Please assess the completion status of the following clinical trial:

Trial Title: SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* New diagnosis of histologically confirmed early-stage breast cancer (ESBC), defined as operable Stage I to Stage IIIA breast cancer~* Candidate for adjuvant or neoadjuvant TC chemotherapy~* Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2~* Absolute neutrophil count (ANC) ≥ 1.5×10\^9/L~* Platelet count ≥ 100×10\^9/L~* Hemoglobin \> 9 g/dL~* Creatinine clearance \> 50 mL/min~* Total bilirubin ≤ 1.5 mg/dL~* Aspartate Aminotransferase per Serum Glutamic-Oxaloacetic Transaminase (AST/SGOT) and Alanine Aminotransferase per Serum Glutamic-Pyruvic Transaminase (ALT/SGPT) ≤ 2.5× Upper Limit of Normal (ULN).~* Alkaline phosphatase ≤ 2.0×ULN~Key Exclusion Criteria:~* Active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of the cervix) or life-threatening disease~* Locally recurrent or metastatic breast cancer~* Known sensitivity to E. coli -derived products or to any products to be administered during dosing~* Concurrent adjuvant cancer therapy~* Previous exposure to filgrastim, pegfilgrastim, or other G-CSF products in clinical development within 12 months prior to the administration of study drug~* Active infection, receiving anti-infectives, or any serious underlying medical condition that would impair ability to receive protocol treatment~* Prior bone marrow or stem cell transplant~* Use of any investigational drugs, biologics, or devices within 30 days prior to study treatment or plans to use any of these during the course of the study~* Radiation therapy within 30 days prior to enrollment~* Major surgery within 30 days prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: SPI-2012 and Docetaxel + Cyclophosphamide (TC) (Type: EXPERIMENTAL): Participants received SPI-2012 13.2 milligram (mg)/0.6 milliliter (mL) (3.6 mg Granulocyte Colony-Stimulating Factor \[G-CSF\]) fixed-dose subcutaneous (SC) injection once per cycle on Day 2 of each cycle up to Cycle 4 (each cycle was 21 days), approximately 24-26 hours after TC chemotherapy administration. TC chemotherapy was administered on Day 1 of each cycle and included Docetaxel 75 mg/m\^2 intravenous (IV) infusion and Cyclophosphamide 600 mg/m\^2 IV infusion per institute's standard of care.
- Arm 2: Pegfilgrastim and Docetaxel + Cyclophosphamide (TC) (Type: EXPERIMENTAL): Participants received pegfilgrastim 6 mg SC injection once per cycle on Day 2 of each cycle up to Cycle 4 (each cycle was 21 days), approximately 24-26 hours after TC chemotherapy administration. TC chemotherapy on Day 1 of each cycle included Docetaxel 75 mg/m\^2 IV infusion and Cyclophosphamide 600 mg/m\^2 IV infusion per institute's standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).